← Human Trials & Peer-Reviewed Studies
Oral vitamin D supplementation on the prevention of peritoneal dialysis-related peritonitis: A pilot randomised controlled trial.
Plain-language guide to PMID 37408329 (2024): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc.
Key Facts
- PMID
- 37408329
- Journal
- Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis
- Year
- 2024
- Study type
- Randomized Controlled Trial
- Authors
- Zhang YH et al. (6 authors)
- DOI
- 10.1177/08968608231182885
What This Study Did, in Plain Language
What Was Tested
Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.
Their objective is to examine the feasibility of conducting a large, randomised controlled trial to determine the effects of vitamin D supplementation on the risk of PD-related peritonitis.
Who Took Part
Patients receiving PD who had recovered from a recent episode of peritonitis between 30 September 2017 and 28 May 2020.
How the Study Was Run
The design is described as randomized, double-blind, open-label and pilot.
Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.
Blinding on both sides kept the participants and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.
Nothing was hidden in this open-label Vitamin D, K2, Magnesium and Zinc study: the participants and staff both knew the treatment.
It is described as a pilot, a small early test of whether a larger Vitamin D, K2, Magnesium and Zinc study would be practical.
Pilot, prospective, open-label randomised controlled trial.
Peking University First Hospital, China.
What Was Measured
PubMed files the paper under topics including Pilot Projects, Peritoneal Dialysis, Vitamin D, Peritonitis, Dietary Supplements and Vitamin D Deficiency.
Author keywords: 25-Hydroxyvitamin D, kidney diseases, natural vitamin D3 and randomised controlled trial.
What This Means in Plain Language
The paper is a randomized, double-blind and open-label study of Vitamin D, K2, Magnesium and Zinc.
Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2024 (Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis), a journal based in United States.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.